Headache Clinical Trial
Official title:
Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Impact Questionnaire
The purpose of this study was to investigate cultural adaptation, reliability and validity of the Turkish version of the Headache Impact Questionnaire (HIQ).
The episodic nature of migraine attacks presents a number of difficulties in characterizing disease severity. There are differences in the severity, frequency and intensity of attacks and the general effect of the disease in individuals. Information about any particular attack is not sufficient to characterize the overall severity of the disease. Accordingly, the Headache Impact Questionnaire (HIQ) was developed to evaluate the headache experience over a period of time instead of any headache. Developed to measure the impact and quality of life of individuals suffering from headache, hıq evaluates the frequency and duration of headache, the degree of pain severity, daily life activities, disruptions in work or school life, the influence of the individual's leisure activities and other symptoms that may occur. HIQ consists of 16 items and the higher the score shows the seriousness of the impact. The study is planned with 80 individuals with complaint of headache. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in HIQ, Migraine Disability Assessment Questionnaire, Headache Impact Test-6 and Short Form-36.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03472872 -
A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache
|
Phase 4 | |
Withdrawn |
NCT05410366 -
Safe Harbors in Emergency Medicine, Specific Aim 3
|
||
Withdrawn |
NCT02866084 -
Neuromodulation Treatment of Vestibular Migraines
|
N/A | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Not yet recruiting |
NCT04352218 -
Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache
|
Phase 2 | |
Completed |
NCT02734992 -
Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers
|
N/A | |
Completed |
NCT01327118 -
Prostaglandin F2alpha in a Human Headache Model
|
N/A | |
Completed |
NCT01153789 -
Study of Oculomotor Dysfunction Leading to Children Vertigo
|
N/A | |
Not yet recruiting |
NCT00969995 -
Identification of Inflammatory Markers in Migraine Patients
|
N/A | |
Not yet recruiting |
NCT00752921 -
Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache
|
Phase 4 | |
Terminated |
NCT00291395 -
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00212810 -
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
|
Phase 4 | |
Completed |
NCT00263094 -
An End to the Yom Kippur (and Ramadan) Headache
|
N/A | |
Completed |
NCT00135122 -
Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
|
Phase 3 | |
Completed |
NCT02475005 -
An Intervention to Improve Adolescent Headache Self-management
|
N/A | |
Completed |
NCT03163901 -
The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury
|
N/A | |
Completed |
NCT01664585 -
Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life
|
N/A | |
Completed |
NCT04632420 -
Evaluation of Headache and Childbirth in a Chronic Pain Population
|
||
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|